MYGN Myriad Genetics Inc.

Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work

Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work

SALT LAKE CITY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Great Place To Work® and Fortune magazine have named Myriad Genetics to the .

The highly competitive list is based on the analysis of survey responses from over 208,000 employees from Great Place To Work Certified™ companies in the health care industry. Earlier this year, , and  said the company is a great place to work – 29 percentage points higher than a typical U.S. company.

“This Fortune Best Workplaces in Health Care recognition is a testament to our commitment of inspiring a dynamic and diverse culture, where career development is prioritized, and all teammates have equal opportunity to grow and make a difference in our patients’ lives,” said Shereen Solaiman, chief people officer, Myriad Genetics. “We’re grateful for the passion, diverse talents and enthusiasm our teammates bring to the global Myriad workforce every day to help fulfill our mission of advancing the health and well-being for all.”

Great Place To Work determines its lists using its proprietary For All™ Methodology to evaluate and certify thousands of organizations in America’s largest ongoing annual workforce study, based on over 1.3 million survey responses and data from companies representing more than 7.5 million employees this year alone. Survey responses reflect a comprehensive picture of the workplace experience.

For more information about careers at Myriad, please visit: .

About Myriad Genetics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit .

About the Fortune Best Workplaces in Health Care List

Great Place To Work selected the 2023 Fortune Best Workplaces in Health Care by gathering and analyzing confidential survey responses from more than 208,000 employees at Great Place To Work Certified organizations in the health care industry. Company rankings are derived from 60 employee experience questions within the . Great Place To Work determines its lists using its proprietary For All™ Methodology to evaluate and certify thousands of organizations in America’s largest ongoing annual workforce study. This year alone, 1.3 million survey responses were received and data from companies representing more than 7.5 million employees.

About Great Place To Work®

As the global authority on workplace culture, Great Place To Work brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Its proprietary platform and For All™ Model helps companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified or receiving recognition on a coveted Best Workplaces™ List.

Follow Great Place To Work on , , and or visit and to learn more.

About Fortune

The Fortune mission is to change the world by making business better. We achieve that by providing trusted information, telling great stories, and building world-class communities. We measure performance by rigorous benchmarks. And we hold companies accountable. Our goal is to make Fortune a force for good through its second century and beyond. For more information, visit .

Media Contact:

Glenn Farrell

(385) 318-3718

Investor Contact:

Matt Scalo

(801) 584-3532



EN
06/09/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Myriad Genetics Inc.

 PRESS RELEASE

Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel

Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations SALT LAKE CITY, Oct. 14, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has added two genes, F8 and FXN, to the . “At Myriad Genetics, we carefully design the Foresight panel to prioritize clinical significance, selecting genes based on condition severity, prevalence, actionability, and guidelines,” sai...

 PRESS RELEASE

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion...

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy SALT LAKE CITY and BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. This partnership will leverage Myriad’s advanced laboratory capabilities in the U.S. to support global test...

 PRESS RELEASE

Myriad Genetics Announces Precise MRD Clinical Data Published in The L...

Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced The Lancet Oncology published a highlighting the performance of Myriad’s molecular residual disease (MRD) test, Precise® MRD, in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC). One of the goals of this study was to determine whether patients with oligometastatic ccRCC could benefit from incorporating ultrasensitive MRD testing into t...

 PRESS RELEASE

New Meta-Analysis Demonstrates that Access to the GeneSight Test Can S...

New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression Results published in the Journal of Clinical Psychopharmacology SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the of a new meta-analysis of six prospective controlled studies1 that included 3,532 adults with major depressive disorder (MDD). The meta-analysis showed that when ® Psychotropic test results were available to treating clinicia...

 PRESS RELEASE

Myriad Genetics to Participate in Upcoming Investor Healthcare Confere...

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences SALT LAKE CITY, Aug. 27, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences. The Wells Fargo Healthcare Conference with a fireside chat on Thursday, Sept. 4 at 3:45pm ET.The Morgan Stanley Annual Global Healthcare Conference with a fireside chat on Wednesday, Sept. 10 at 7:45am ET. Links to the live and archived webcasts of both presentations can be viewed at . About ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch